Biotech Venture Funding Tracker 2026
Private financings — Company, date, round, investors, therapeutic area, and a one-line
"what they do."
Last updated:
17 May 2026
Unlock the full 2026 VC tracker + get deal alerts
Subscribe (free) to access the full table and get new financings as they land — in
~5 mins/day, read by 2,000+ VC, BD&L, and public biotech investors.
No spam. Unsubscribe anytime.
2026 biotech venture funding snapshot
- 77 venture financings are now tracked in total for 2026 so far.
- Largest disclosed financing so far: Isomorphic Labs at US$2.1B, followed by Earendil Labs at US$787M disclosed, Parabilis Medicines at US$305M, Beeline Medicines at US$300M, and Anagram Therapeutics at US$250M.
- The 2026 tape has been broad rather than single-theme, spanning obesity / cardiometabolic, autoimmune / immunology, oncology, CNS / neuropsychiatry, genetic medicines / RNA, ophthalmology, AI-enabled platforms / TechBio, longevity / epigenetic reprogramming, tumour-microenvironment ADCs, and cell therapy / in vivo CAR.
- A notable read-through is that investors are still funding both late-stage / near-commercial execution stories and next-generation platform or modality bets — from Phase 2/3 and launch-preparation companies to earlier AI, biologics, antibody, RNA, peptide, gene therapy, and cell therapy platforms with clear lead-asset narratives.
- The latest refresh added CREATE Medicines, Anagram Therapeutics, and Isomorphic Labs, with Isomorphic’s US$2.1B Series B resetting the top of the 2026 private-financing leaderboard and Anagram’s US$250M Blackstone Life Sciences investment underscoring continued appetite for late-stage, specialty biopharma execution stories.
May 2026
CREATE Medicines
Series B
Date:
14-May-2026
|
Size:
US$122M
|
Therapeutic area:
Cell therapy / in vivo CAR / autoimmune disease and oncology
Investors:
Co-led by ARCH Venture Partners, Newpath Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other existing investors
What they do:
Biotechnology company developing RNA-based in vivo CAR therapies designed to reprogram immune cells inside the body. Proceeds will advance its in vivo CAR pipeline across autoimmune disease and oncology, supporting clinical development and platform expansion.
Isomorphic Labs
Series B
Date:
12-May-2026
|
Size:
US$2.1B
|
Therapeutic area:
AI-enabled drug discovery / TechBio
Investors:
Led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund
What they do:
AI-first drug design and development company spun out of Google DeepMind. Proceeds will support scaling of its AI drug-design engine, continued expansion of the team, and advancement of its internal and partnered drug candidate pipeline.
Anagram Therapeutics
Blackstone Life Sciences Investment
Date:
07-May-2026
|
Size:
US$250M
|
Therapeutic area:
GI / enzyme replacement / exocrine pancreatic insufficiency
Investors:
Blackstone Life Sciences
What they do:
Clinical-stage biopharma developing ANG003, an oral enzyme replacement therapy for exocrine pancreatic insufficiency, including EPI due to cystic fibrosis, pancreatic cancer, and related disorders. The financing supports Phase 2b and Phase 3 development, manufacturing scale-up, and broader preparation for potential commercialization.
Kanvas Biosciences
Series A
Date:
06-May-2026
|
Size:
US$48M
|
Therapeutic area:
Oncology / microbiome therapeutics
Investors:
Led by DCVC Bio, with participation from Gates Foundation, S32, Chugai Venture Fund, Amplify Partners, ReMY Investors & Consultants, Setpoint Medical, JAZZ Venture Partners, and existing investors including DCVC and Lions Capital
What they do:
Microbiome therapeutics company developing live biotherapeutic approaches for cancer. Proceeds will advance the company’s lead immuno-oncology drug candidate, designed to improve the efficacy of immunotherapy in solid tumours, while supporting platform development and clinical translation.
CellCentric
Series D
Date:
06-May-2026
|
Size:
US$220M
|
Therapeutic area:
Oncology / multiple myeloma
Investors:
Led by Venrock Healthcare Capital Partners, with participation from Pfizer, Fidelity Management & Research Company, Sofinnova Partners, RA Capital Management, Forbion, Janus Henderson Investors, TCGX, EQT Life Sciences, Avego BioScience Capital, Piper Heartland Healthcare Capital, Oxford Science Enterprises, Morningside, Schroders Capital, British Patient Capital, Cancer Research Horizons, M Ventures, and others
What they do:
Clinical-stage oncology biotech developing inobrodib, a first-in-class oral p300/CBP inhibitor, for multiple myeloma. The financing supports registration-enabling trials and continued development of inobrodib in advanced blood cancers, with the company also positioning around potential IPO optionality.
Cytospire Therapeutics
Series A
Date:
05-May-2026
|
Size:
£61M / US$83M
|
Therapeutic area:
Oncology / immune cell engagers
Investors:
Led by 4BIO Capital, with participation from Servier Ventures, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth, LifeArc Ventures, Modi Ventures, Medical Incubator Japan, and Pathway Bioventures
What they do:
UK biotech developing differentiated multispecific immune cell engager antibodies designed to activate pan-gamma delta T cells. Proceeds will advance the company’s pipeline, including CYT X300 for EGFR-positive cancers, toward clinical proof-of-concept.